NuVasive traded at $39.75 this Thursday August 31st, decreasing $0.91 or 2.24 percent since the previous trading session. Looking back, over the last four weeks, NuVasive lost 2.67 percent. Over the last 12 months, its price fell by 6.95 percent. Looking ahead, we forecast NuVasive to be priced at 38.89 by the end of this quarter and at 36.43 in one year, according to Trading Economics global macro models projections and analysts expectations.
NuVasive, Inc. is a developer of specialty spinal implants into a global medical technology company that is delivering integrated solutions for spine surgery. The Company's portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, and intraoperative neuromonitoring technology and service offerings. The Company's surgical access instruments include its Maxcess integrated split-blade retractor system. The Company's neuromonitoring software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support. The Company's Advanced Materials Science portfolio of specialized spinal implants is designed to advance spinal fusion by improving the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone (PEEK).